Drug Name: Rezlidhia Active Ingredient: olutasidenib Indications: To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation Approval Date: 12/1/2022 Company: Forma Therapeutics,…
Drug Name: Tzield Active Ingredient: teplizumab-mzwv Indications: To delay the onset of stage 3 type 1 diabetes Approval Date: 11/18/22 Company: Provention Bio, Inc. (a Sanofi company) Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761183s000lbl.pdf
Drug Name: Elahere Active Ingredient: mirvetuximab soravtansine-gynx Indications: To treat patients with recurrent ovarian cancer that is resistant to platinum therapy Approval Date: 11/14/2022 Company: ImmunoGen, Inc Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761310s000lbl.pdf
Drug Name: Tecvayli Active Ingredient: teclistamab-cqyv Indications: To treat relapsed or refractory multiple myeloma among adults who have received at least four specific lines of therapy Approval Date: 10/25/2022 Company:…
Drug Name: Imjudo Active Ingredient: tremelimumab Indications: To treat unresectable hepatocellular carcinoma Approval Date: 10/21/2022 Company: AstraZeneca Pharmaceuticals LP Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761289s001lbl.pdf
A cheap malaria vaccine that can be produced on a massive scale has been recommended for use by the World Health Organization (WHO). The vaccine has been developed by the…
According to a paper on Lancet Neurobiology, stroke mortality is projected to increase to 9.7 million deaths by 2050. As part of recommendations by World Stroke Organization, the authors have…
There will be better protection against severe disease, hospitalization, and death from COVID-19 in the coming months now that newly updated (2023–2024 formula) mRNA COVID vaccines are available. The new shots are…
Drug Name: Relyvrio Active Ingredient: sodium phenylbutyrate/taurursodiol Indications: To treat amyotrophic lateral sclerosis (ALS) Approval Date: 9/29/2022 Company: Amylyx Pharmaceuticals, Inc Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/216660s000lbledt.pdf
Drug Name: Lytgobi Active Ingredient: futibatinib Indications: To treat intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements Approval Date: 9/30/2022 Company: Taiho Oncology, Inc…